Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Wendy Stock

Showing results (251-260 of 322) with videos related to

Pageof 33
Sort By:
Blood Advances|December 21, 2018
Randomized trial of 10 days of decitabine ± bortezomib in untreated older patients with AML: CALGB 11002 (Alliance)Gail J Roboz, Sumithra J Mandrekar, Pinkal Desai, et al.
Nature Reviews. Clinical Oncology|September 1, 2025
Apoptosis-targeting BH3 mimetics: transforming treatment for patients with acute myeloid leukaemiaAntonino Glaviano, Ellen Weisberg, Hiu Y Lam, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 22, 2012
High-dose vincristine sulfate liposome injection for advanced, relapsed, and refractory adult Philadelphia chromosome-negative acute lymphoblastic leukemiaSusan O'Brien, Gary Schiller, John Lister, et al.
The Lancet. Oncology|August 29, 2017
Guadecitabine (SGI-110) in treatment-naive patients with acute myeloid leukaemia: phase 2 results from a multicentre, randomised, phase 1/2 trialHagop M Kantarjian, Gail J Roboz, Patricia L Kropf, et al.
Blood Advances|January 26, 2021
Comparison of CALGB 10403 (Alliance) and COG AALL0232 toxicity results in young adults with acute lymphoblastic leukemiaAnjali S Advani, Eric Larsen, Kristina Laumann, et al.
Biorxiv : the Preprint Server for Biology|February 24, 2023
Epigenomic mapping in B-cell acute lymphoblastic leukemia identifies transcriptional regulators and noncoding variants promoting distinct chromatin architecturesKelly R Barnett, Robert J Mobley, Jonathan D Diedrich, et al.
JCO Oncology Practice|January 22, 2024
Characteristics of Health Care Settings Where Adolescents and Young Adults Receive Care for ALLJulie A Wolfson, Allison C Grimes, Michelle Nuno, et al.
Blood Advances|December 24, 2019
Therapy-related acute lymphoblastic leukemia is a distinct entity with adverse genetic features and clinical outcomesCaner Saygin, Ashwin Kishtagari, Ryan D Cassaday, et al.
Haematologica|January 19, 2023
Clinical and molecular response of acute myeloid leukemia harboring non-canonical <i>FLT3</i> N676K driver mutations to contemporary FLT3 inhibitorsGregory W Roloff, Frank Wen, Aubrianna Ramsland, et al.
Cancer Cell|April 9, 2024
Single-cell systems pharmacology identifies development-driven drug response and combination therapy in B cell acute lymphoblastic leukemiaXin Huang, Yizhen Li, Jingliao Zhang, et al.
Pageof 33

Showing results (251-260 of 322) with videos related to

Sort By:
Pageof 33
Blood Advances|December 21, 2018
Randomized trial of 10 days of decitabine ± bortezomib in untreated older patients with AML: CALGB 11002 (Alliance)Gail J Roboz, Sumithra J Mandrekar, Pinkal Desai, et al.
Nature Reviews. Clinical Oncology|September 1, 2025
Apoptosis-targeting BH3 mimetics: transforming treatment for patients with acute myeloid leukaemiaAntonino Glaviano, Ellen Weisberg, Hiu Y Lam, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 22, 2012
High-dose vincristine sulfate liposome injection for advanced, relapsed, and refractory adult Philadelphia chromosome-negative acute lymphoblastic leukemiaSusan O'Brien, Gary Schiller, John Lister, et al.
The Lancet. Oncology|August 29, 2017
Guadecitabine (SGI-110) in treatment-naive patients with acute myeloid leukaemia: phase 2 results from a multicentre, randomised, phase 1/2 trialHagop M Kantarjian, Gail J Roboz, Patricia L Kropf, et al.
Blood Advances|January 26, 2021
Comparison of CALGB 10403 (Alliance) and COG AALL0232 toxicity results in young adults with acute lymphoblastic leukemiaAnjali S Advani, Eric Larsen, Kristina Laumann, et al.
Biorxiv : the Preprint Server for Biology|February 24, 2023
Epigenomic mapping in B-cell acute lymphoblastic leukemia identifies transcriptional regulators and noncoding variants promoting distinct chromatin architecturesKelly R Barnett, Robert J Mobley, Jonathan D Diedrich, et al.
JCO Oncology Practice|January 22, 2024
Characteristics of Health Care Settings Where Adolescents and Young Adults Receive Care for ALLJulie A Wolfson, Allison C Grimes, Michelle Nuno, et al.
Blood Advances|December 24, 2019
Therapy-related acute lymphoblastic leukemia is a distinct entity with adverse genetic features and clinical outcomesCaner Saygin, Ashwin Kishtagari, Ryan D Cassaday, et al.
Haematologica|January 19, 2023
Clinical and molecular response of acute myeloid leukemia harboring non-canonical <i>FLT3</i> N676K driver mutations to contemporary FLT3 inhibitorsGregory W Roloff, Frank Wen, Aubrianna Ramsland, et al.
Cancer Cell|April 9, 2024
Single-cell systems pharmacology identifies development-driven drug response and combination therapy in B cell acute lymphoblastic leukemiaXin Huang, Yizhen Li, Jingliao Zhang, et al.
Pageof 33